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Because woundin.g the epidermis increases proteo-
lytic activity and because disorders associated with 
barrier dysfunction have elevated protease activity, 
we studied the effect of protease inhibitors on the 
time course of barrier recovery and on the develop-
ment of epidermal hyperplasia induced by repeated 
injury. After injuries to the epidermis produced by 
tape stripping, acetone treatment, or detergent (SDS) 
treatment that disrupt the barrier, a single applica-
tion of 5% tranexamic acid [4-(aminomethyl)cyclo-
hexane carboxylic acid, t-AMCHA], a well known 
anti-plasmin reagent, accelerated barrier recovery in 
both hairless 1nouse and human skin. In contrast, 
neither aminocaproic acid nor aminobutyric acid, 
inactive analogs of t-AMCHA, affected the time 
course ofbarrier recovery. Several trypsin-like serine 
protease inhibitors, e.g., leupeptin, TLCK, and 
PMSF, also accelerated barrier repair. In contrast 
other types of protease inhibitors, e.g., EDTA, pep-
T he outermost layer of the skin, the stratum com cum (SC), is in. contact with the env ironment and hence is susceptible to a wide variety of toxic insults. Injuries to the skin may be i11duced by contact with solvents or detergents or via mechani cal injury such as tape 
stripping and can disrupt the cutaneous permeabili ty barrier. T he 
cutaneous permeability barrier is localized to the extracellular 
lamellar membranes of the SC (Elias el a/, 1993) . Acute disruption 
of the SC barrier by tape stripping, sol vent treatment, or detergent 
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statin, N-ethylmaleimide, chymostatin, and TPCK, 
did not accelerate barrier recovery. We next evalu-
ated the effects of daily topical application of t-
AMCHA on epidermal hyperplasia, induced by re-
peated tape stripping or acetone treatment for 7 d. 
The degree of hyperplasia, quantified by the mea-
surement of epidermal thickness, was reduced in 
both models by repeated applications of t-AMCHA. 
Finally, proteolytic activity in both human and 
mouse epidermis increased 1-2 h after epidermal 
injuries that disrupt the barrier. These results dem-
onstrate that the inhibition of plaSinin, a serine pro-
tease, accelerates barrier recovery and inhibits the 
epidermal hyperplasia induced by repeated barrier 
disruption, perhaps by decreasing the extent of atten-
dant epidermal injury. Key words: stratmn comemn./ 
tra.usepideJ'Ina.lwa.ta losslpl'Oteases. J Invest Dermatol 109: 
84-90, 1997 
treatment elicits a homeostatic response in the epidermis that 
rapidly restores normal banier function. T his repair response 
includes the immediate secretion of pre-formed lamellar bodies, an 
increase in epidermal lipid synthesis, the formation of new lamellar 
bodies with further secretion and the extracellular remodeling of 
secreted lame ll ar-body-derived lipids (Elias et a/, '1 993; Proksch et 
a/, 1993). These changes lead to the restoration of lipid-enriched 
membranes in the SC resulting in normalization ofban:ier ftm clion . 
The highly predictable and reproducible kinetics of the recovery 
response can be exploi ted to (i) link various components of tbe 
repa ir respon~e to a partic ular phase of the recovery response 
(Talj ebin.i et a/, 1996), (ii) elicit previously undetected defects in 
barrier function, e.g., in chronologie aging, (Ghadially el al, 1995), 
or (iii) ascertain whe ther various topical treatments inhibit or 
accelerate barrier recovery (Man e/ al, l993b, 199Sb) . For example, 
we have recently reported tha~ certain topica lly applied physiologic 
lipid mixtures inhibit barrier recov.cry (Man et nl, 1993b), whereas 
other physiologic and inert lipid mixtures allow normal recovery or 
even accelerate the repair response (Man et a/, 199Sa, 1996) . 
Proteolytic enzyme activity has been demonstrated in the SC by 
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Table I. Effect of Different Classes of Protease Inhibitors 
on Barrier Recovery" 
% Recovery 
Inhibi tor 2 h 4 h 8 h 12 h 
Metalloproteases 
Control 28.8 :!:: 9.0 50.8 :!:: 11 .6 80.7 :!:: 7.2 91.0 :!:: 3.2 
(NS1') (NS) (NS) (NS) 
EDTA 29 .9 :!:: 10.2 51.6:!:: 10.1 84.0 :!:: 8.0 90 .6 :!:: 7.0 
Aspartate protcases 
Control 34 .9 :!:: 7.4 49.0:!:: .11.1 77 .1 :!:: 5.5 83.8 :!:: 3 .3 
(NS) (NS) (NS) (NS) 
Pcpstatin 35.9 :!:: 3.9 44 .7 :!:: 10.4 81.6 :!:: 8.9 85.8 :!:: 9 .1 
Cysteine proteases 
Control 34.0 :!:: 5.0 63 .7 :!:: 5.6 70.7 :!:: 7.0 76.4 :!:: 5 .9 
(NS) (NS) (NS) (NS) 
E64 30.5 :!:: 4.1 61 .8:!::7.1 66. 1 :!:: 3.8 72.0 :!:: 5. 7 
Serine proteases 
Control 35. 1 :!:: 5.6 48.4 :!:: 7.4 75.4 :!:: 6.1 84 .6 :!:: 0.8 
(NS) (p < 0.02) (NS) (p < 0.05) 
PMSF 44 .3 :!:: 5.6 61.1 :t 3.7 82.2 :!:: 2.2 90.6 :!:: 2.3 
''Serine protease inhibi tion acce lerates barrier recovery in mouse skin after barrier 
disruptio n. T he flank sltin was treated with cape stripping until TEWL reached 8.5 ± 
1.5 mg per cm2 per h. Immediately afte r barrier disruption 100 J.l.l of a water solution 
conta ining '10 mM PMSF or EDTA, 10 J.I.M pcpstatin, I mM EG4 or water alone 
(control) was applie d to the treated area. TEWL was measured at the times indicated 
after barrier disruption. Values arc th e mean ::!::: SO (n = 4). 
/J p v;-t lucs are in parentheses and compare control and inhibi tor va lu es. NS, not 
sig:nifi canL 
several laborato ries (Hausson el a/, 1994; Suzuki el a/, 1994) . It h as 
been h ypothes ized that these proteases are important for the 
reg ulate d d esquamatio n of the SC and/or the hydrolysis of filaggrin 
to osmotically active amino acids important for hydration (Scott 
and Harding, 1986; Hausson et a/, 1994; Suzulci et a/, 1994). 
Wounding the epidermis increases proteolytic activity, which is 
thought to be important for wound repair (Gron d ahl-Hau sen et. a/, 
1988; Romer el a/, 1991, 1994). Moreover, abnormally high 
c utaneous proteolytic ac tivity has been observed iJ1 several slcin 
diseases associated with abnormal cutaneous barrier function, such 
as atopic d e rmatiti s, contact dermatitis, and psoriasis Qen sen et a/, 
1988, 1990; Wiedow et al, 1992; Spiers et a/, 1. 994). Furthe rmore , 
psmiatic lesions display inc reased activ ity and expression of plas-
tnin ogen Qense n et a/, 1988, 1990; Spiers et a/, 1994). Because of 
the increase in proteolytic activity after e pide rmal i.njm-y and the 
associati o n of in creased proteolytic activity with disease states 
associate d with impaire d b arrie r function, w e hypothes ize d that 
increased p rotease activity might be detrimental to barrier ho-
m eostasis. To test this hy pothes is, we compared the effect of vatious 
classes of protease inhibitors on the lcinetics of barrier recovery after 
barrier disrup tion of normal m o u se and human skin by tape 
stt·ippin g, acetone treatment, or sodium dodecyl sul £1 te (SDS) 
treatment. 
MATEJUALS AND METHODS 
Mouse Studies Male hairless mice (SKH1) were purchased from C harl es 
River (Wilmington, MA). Animals were 7- 10 wk of age at the time of 
study. Phenylmethylsulfonyl fluoride (PMSF), ethylenediamine tetraacctic 
acid, pepstatin , L-trnlls-epoxysuccinyl- leucylamide-(4-guanidino)-butane 
(E64), chymostatin, L-1-chloro-3-( 4-tosylam.ido )-4-phenyl-2-butanone 
(TPCK). trans-4-(aminomethyl)-cyclohexane carbo,_-ylic acid (t-AMCHA), 
anunocaproic acid, and am.inobutyric acid were purchased from Sigma (St. 
Louis, MO). Lcupcptin was purchased from Peninsula Laboratories (San 
Carlos , CA), and L-1-chloro-3-(4-tosylamido)-7-amino-2-heptanone hy-
drochloride (TLCK) liom Fluka (Ronkonkoma . NY). 
Barrier disruption was aclueved by repeated applications of cellophane 
tape (3M, St. Paul , MN) on mouse flank skin . Alternatively. the barrier was 
disrupted with repeated applications of cotton balls soaked w ith either 
acetone or 1 o;., SDS for 5 to 10 min . Each procedure was terminated when 
transcpidcrma1 water loss (TEWL) levels reached 8.5 :t 1 .5 mg per cm2 per 
h (range). Immedia tely after ban;er di sruption 100 f.d of an aqueous solu tion 
contain ing 10 mM PMSF. ethylenediamine tctraacetic acid, 10 JJ.M pcpsta-
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tin, 1 mM E62, leupeptin, TLCK, chymostatin. TPCK, 320 mM t-AMCHA 
(5%), 380 mM anunocaproic acid, or 490 mM aminobutyric acid, or water 
alone (control) was applied to the treated area. T he doses employed for each 
inlubitor were approximately 10 times the effective concentration required 
for protease inhibition i11 11itro (Beynon et a/, 1989) . TEWL was measured 
before barrier disruption, immediately after barrier disruption, and as 
indicated by using an electrolytic water an alyzer (Mecca, Warrington, PA) , 
as described previously (Menon eta/, 1985; Grubauer et nl, 1989) . 
Epidermal hyperplasia was induced by repeated disruption of the barrier 
by treatment with cellophane tape or acetone twice a day for 7 d as 
described in detai l previously (Denda eta/, 1996) . Briefly, the animals were 
treated at approximately 8 a.m. ru1d 5 p.m. and each procedure was 
terminated when TEWL reached 8.5 :!:: 1.5 mg per cm2 per h (range). 
Barrier function did not return to normal between treatments. Just after 
each treatment 100 JJ.l of a water solution containing 0.064 M t-AMCHA. or 
water alone was applied to the treated area. Mter the last treatment, the 
mice were killed and the skin removed for histologic studies. 
Human Studies Barrier disruption was aclueved by repeated applications 
ofCellotapc (Nicluban, Tokyo, j apan) on the volar forearm ofhealthy male 
volunteers until TEWL = 8.5 :!:: 1.5 mg per cm 2 per h (range). Altenla-
tively, the barrier was disrupted by repeated application of acetone (30 - 45 
min) or 1% SDS (5- 10 min). TEWL was measured with an electrolytic 
water analyzer after barrier disruption at the times indicated. 
Microscopy and Morphometries After fixation Mth 4% paraformalde-
hyde, the skin specimens (volar fo rearm biopsies) were embedded in 
paraffin and stained with hematoxylin and eosin. Five cross-sections were 
taken from difl:e rent parts of each treated area. On each section , 10 points 
were selected at random; the thickness of the nucleated epidernus was 
measured with an optica l mkrometcr and the m ean value was calcttlated. 
Measurements were carried out by an observer w ho did not know the origin 
or prior tream1ent of the sample groups. 
Enzyme Localization l11 sit11 zymography was carried out on skin 
samples obtained from the inner forearm of healthy males 2 h after tape 
stripping (TEWL = 10 mg/cm2/ h). Control samples were obtained from an 
adjacent or contralateral un treated area. Samples were immediately embed-
ded and frozen in O.C.T. (Miles , Elkhart, IN) ~vithout fixation. Blocks of 
embedded tissue were sto red at - 70°C tmtil sectioned . !11 sit11 zymography 
was carried out by a modification of the methods used by Spiers et nl (1994) 
and Galis et nl (1994). Briefly, the overlay solu tion comau1cd 200 JJ.I ofPBS, 
266 JJ.l of2 .5% agar solution in water, 80 JJ.l of a so lution of purified human 
plasminogen (0. 9 mg per ml), 134 JJ.I of a 1% casein-fluorescein isotluocya-
Table U . Effect of Serine Protease Inhibitors on 
Barrier Recovery" 
% Recovery 
Inhibitor 2 h 4 h 8 h 12 h 
Trypsin-like 
E"-perimcnt 1 
Control 7.5 :t 12.1 41.3 :t 10.3 67.5 :!:: 6.3 72 .6:!:: 9.7 
(p < 0.03) 1' (P < 0.02) (NS) (NS) 
Leupeptin 26.1 :!:: 4.8 59.1 :t 5.8 73.4 :!:: 6.5 78.8 :!:: 3.8 
E"-perimcnt 2 
Control 20 .7 :!:: 5.5 40.5 :!:: 4.3 61.5 :!:: 3.9 74.8 :!:: 2.6 
(p < 0.03) (NS) (p < 0.006) (NS) 
TLCK 23.9 :!:: 2.2 49.9 :t 10.0 74.2 :t 4.8 82.2 :!:: 4.4 
C hym otrypsin- like 
Experiment 3 
Control 16.6 :t 7.8 37 .1 :t 16.6 67.9:t6. 1 81.1 :!:: 2.2 
(NS) (NS) (NS) (NS) 
C hymostatin 14.9:!:: 6.7 38 .8 :t 10.5 63.5 :t 4.9 82.5 :!: 1.0 
Experiment 4 
Control 33.6 :!:: 5.8 50.3 :t 10.5 79.7 :!:: 3.1 82.9 :t 5.5 
(NS) (NS) (NS) (NS) 
TPCK 35.3 :t 5.5 52.5 :!:: 8.3 74.3 :!:: 6.4 85.1 :t 5.8 
''Trypsin- like serine protease. inhibition nccelcral·cs barrier recovery in mouse skin 
after barrier disruption. T he Annk skin was treated w ith tape stripping until TE\VL 
rc:1chcd 8.5 ± 1.5 mg pe r cm 2 per h. Im mediately after barrier disruption 100 l·d of a 
water solution cont<~ining l mM lcupcptin. TLCK. chymostatin , TPCK. or wnter alone 
(control) was applied to the treated area. TE\XIL was measured at the times ind icated 
:1ftcr b:-~tTi cr d isruption . V:1 lucs arc m ea n ± SD (n = 4) . 
11 p valu es arc in pnrenthescs and compare control and inhibitor v::tlues. NS, not 
significa nt. 
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Figure 1. t-AMCHA accelerates barrier recovery in mouse skin after tape stripping (A ), acetone treatment (B), or SDS treatment (C). T he 
Rank skin was treated un til TEWL reached 8.5 ± 1.5 mg per cm2 per h. Immedi ately after barrier disruption 100 pJ oft-A.MCHA solution (0.32 M) or water 
alone (control) was applied to the treated area. TEWL was measured at the times indicated after barrier disruption. Error bnrs, SD (n = 4) . *p < 0.05; ** p < 
0.01; *''* p < 0.005. 
nate solution in phosphate-buffered sa line, and 2.4 J.d of 10% sodium azide. 
This overlay mixture was prepared at 50°C, and 50 pJ of the mixture was 
applied to prewarmed 1 0-p,m-thick cryostat sections mounted on Superfrost 
slides and spread evenly under glass coverslips (18 X 18 mm) . Slides were 
incubated at 37°C in humid chambers fo r 3 d, and the lysis of the substrate 
was detennined by examination with a fluorescent microscope (Olympus, 
A.H3-RFC, Tokyo, Japan). Loss of fluorescence is indicative of proteolysis. 
Data Analysis T he barrier recovery results are expressed as percent 
recovery because of variations from day to day in the extent of disruption of 
the barrier. In each animal the percent recovery was calcu lated by the 
fo llowing formu la : 1 - [(TEWL immediately after treatment - TEWL at 
indicated time)/(TEWL immediate ly after treatment - baseline TEWL)] X 
100%. Resul ts arc expressed as the mean ± SD. Statistical difFerences were 
determined by a two-tai led Student' s t test because all data were compared 
to simu ltaneously studied contml.s. 
RESULTS 
Our initial experiments tested the abili ty of different classes of 
protease inhibitors to modulate the ki11etics of barrier recovery after 
acute cu taneo us injuries that disrupt the permeabili ty b;m:ier. At the 
doses employed, eth ylenediam in e tetraacetic acid (a m etallopro-
tease inhibitor), pepstatin (an aspartic protease inhibitor), or E64 (a 
cysteine protease in hibitor) did not altered the kinetics of barrier 
recovery (Table 1). In contrast, treatment w ith PMSF, a genera l 
serine protease inhibi tor, sign ifi can tly accelerated barrier recovery 
at 4 and 12 h. 
Serine protease inhibitors can be divided into two gen eral classes: 
tryps in-like and ch ymotrypsin-like. Trypsin-like serine protease 
inhibitors (leupeptin and TLCK) significantly accele rated barrier 
recovery, w h ereas chymotrypsin-like serine protease inhibitors 
[ chymostatin and TPCK h ad little o r no effect on barrier recovery 
(Table II). 
W e next tested the effects of of t-AMCHA, a trypsin-like 
(A) Amino butyric acid 
100 
80 
~ 60 
40 
protease inhibitor that specifically inhibits the formation of plasmin, 
an extracellular serine protease (Reinartz et nl, 1993). As shown in 
Fig 1, topicaJ treatment with t- AMCHA signiftcantly accelerates 
barrier recovery after tape stripping (Fig 1A, 66% faster at 4 h) , 
aceton e treatment (Fig 1B, 140% and 75% faster at 2 and 4 h, 
respective ly), or SDS treatment (Fig 1C, 11-fold and 58% faster at 
2 and 4 h , respectively) . In contrast, minimally active stru c tural 
analogs of t- A MCHA (aminocaproic acid and aminobutyric ac id) 
either de lay o r do not alter the kinetics of barrie r repair (Fig 2). 
We next determined whether t-AMCHA would also influ en ce 
the kinetics of barrier recovery in hurnans. As shown in Fig 3, after 
tape stripping, aceton e treatment, or SDS treatment, t-AMCHA 
markedly accelerate ban;er recovery, a result similar to th at 
observed in mice after barrier disruption. 
Jn recent studies, we demonstrated that repeated disruption of 
the barrier by e ither tape stripping or aceton e treatment for 7 d 
results in cutaneous pathologic changes, including epidermal h y-
perplasia, and that these chan ges are linked to epiderma l injury 
rath e r than barrier disruptio n (Denda et nl, 1996). T herefore, w e 
next asked w heth er t-AMCHA also would .impede the develop-
ment of epidermal hyperplasia. As shown in F igs 4 and 5, 
t-AMCHA treatment greatly decreased the epid erm al h yperplasia 
induced by either repeated tape stripping o r aceton e treatm ent. 
T h ese resu lts show that protease activation contributes to th e 
development of epidermal hyperplasia after stratum corneum in-
jury. 
Because the above studies show that pla smin-type serin e pro-
teases are detrimen tal to ban·ie r h om eostasis and potentially con-
tribute to cutaneous path o logy, we next asked whether injut;es to 
the epi dermi s that result in barrier di sruption stimulate epidermal 
proteolytic activity. As shown in Fig 6, tape stripping induces 
epidermal proteo lytic activity. T his epide rmal proteolytic activi ty 
(B) Amino caproic acid 
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Figure 2. Ana.logs of t-AMCHA ei-
ther delay or do not alter the kinetics 
of barrier repair~ Mouse Rank skin was 
treated with tape stripping until TEWL 
reached 8.5 :!:: 1.5 mg per cm2 per h. 
Immediately after tape stripping 1 00 p,l of 
aminobutyric acid so lu tion (0.49 M) (A), 
aminocaproic acid (0.38 M) (B) , or water 
alone (contro l) was app lied to the treated 
area. TEWL was measured at the times 
indicated after barrier disruption . Error 
hars, SO (n = 4). *p < 0.05. 
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Figure 3 . t -AMCHA accelerates barrier recovery in human skin after tape stripping (A), acetone treatment (B), or SDS treatment (C) . 
Forearm skin was treated until TEWL reached 8.5 ± 1.5 mg per cm 2 per h . Immediately after barrier disruption 100 pJ of t-AMCHA solution (0.32 M) or 
water alone (control) was applied to the treated area . TEWL was measured at the times indicated after barrier disruption. En-or bars, SD (n = 3). *p < 0.05; 
**p < 0.01 . 
Was decreased in plasminogen-free substrate gel, suggesting that a 
major portion of the increase in proteolytic activity in the epidermis 
after tape stripping occurred via the plasminogen/plasmin system. 
Most importantly, the increase in epidermal proteolytic activity 
induced by tape stripping could be markedly inhibited by t-
AMCHA even in the presence of plasminogen. These results 
suggest an important role for the plasminogen/plasmin system in 
the increased epidermal proteolysis that occurs after barrier disrup-
tion. Further, they correlate with the ability of plasminogen/ 
plasmin inhibitors to accelerate banier recovery. 
Figure 4. t-AMCHA treatment decreases epidermal hyperplasia induced by either repeated tape stripping or acetone treatment of mouse 
flank skin. Acetone or tape stripping was carried out twice a day for 7 d until the TEW.L levels reached 8.5 ± 1.5 mg per en/ per h.Just after each treatment, 
100 p.l of a water so lution containing 0.064 M t- AMCHA or water alone was applied to the treated area. Skin samples were fixed and stained with 
hematoxylin and eosin. Afte r either repeated ta pe stripping (A) or acetone (B) epidermal hyperplasia is present in contrast to untreated control (E). t- AMCHA 
treatment of both tape-stripped (C) or acetone-treated skin (D) resu.lts in a decrease in epidermal hyperplasia. Scale bm~ 40 p.m. 
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Figure 5. t-AMCHA treatment decreases epidermal hyperplasia 
induced by either repeated tape stripping or acetone treatment of 
mouse Bank skin. Acetone or tape stripping was carried out twice a day 
for 7 d until the TEWL levels reached 8 .5 :!: 1.5 mg per cm 2 per h. Five 
sections were taken from different parts of each treated area. On each 
section, J 0 points were selected at random. The thickness of the nucleated 
epidermis was measured with an optical micrometer, and the mean va lue 
was calculated. Measurements were carried out in an observer blinded 
f.1shion. En'OI' bars, SD (n = 5). 
DISCUSSION 
Previous studies from our laboratory have shown that injuries to the 
epidermis that disrupt the cutaneous permeability barrier result in a 
homeostatic recovery response that rapidly restores barrier function 
toward normal (Elias et al, 1993; Proksch et al, 1993). Over the 
years, we have identified a number of metabolic responses that 
occur in the underlying epidermis that are important for barrier 
homeostasis. As one would expect, inhibition of each of these 
metabolic processes delays barrier recovery. For example, inhibi-
tion of epidermal lipid synthesis, lamellar body secretion, or 
extracellular processing delays barrier repair (Feingold et al, 1990; 
Holleran el a/, 1991, 1993; Man el a/, 1993a, 1995a, 1995b). 
In the current study, we provide evidence that endogenous 
proteolytic activity, which increases as a consequence of epidermal 
injury, may retard the rate of barrier recovery. By using ;, situ 
zymography, we demonstrated in humans that tape stripping 
increases proteolytic activity in the epidermis. Similar results were 
observed in mice after either tape stripping ot· acetone treatment 
(data not shown). This increase in epidermal proteolytic activity 
required plasminogen and was markedly inhibited by t-AMCHA, 
suggesting that the plasminogen/plasmin system accounts for a 
large part of the increase in epidermal proteolytic activity that was 
induced by barrier disruption. Other investigators have shown that 
wounding the epidermis also activates the plasminogen/plasmin 
system (Grondahl-Hansen et a/, 1988; Romer et a/, 1991, 1994). 
Several different types of protease inhibitors, including metal lo-, 
aspartic, and cysteine protease inhibitors, bad no beneficial effects 
on barrier recovery . In contrast, topical application of severa l 
different serine protease inhibitors accelerate barrier recovery. 
Specifically, tt)'psin-like serine protease inhibitors improve barrier 
recovery whereas chymott)'psin-like serine protease inhibitors had 
no effect. Moreover, t-AMCHA, a serine protease inhibitor that 
prevents the activation of plasminogen by inhibiting binding to cell 
surface receptors (Reinartz et a/, 1993), also enhances barrier 
recovery. Furthermore, t-AMCHA accelerates bart.ie r recovery in 
both mice and humans after severa l unrelated insults, such as tape 
stripping, solvent treatment (acetone) , or detergent treatment (:I 'X, 
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SDS). In contrast, chemically related but inactive analogues of 
t-AMCHA that do not inhibit plasminogen activation have no 
effect on barrier recovet)'. These results suggest that the activation 
of the plasminogen to plasmin, a serine protease, is detrimental for 
barrier homeostasis. The abnormalities in barrier function reported 
in atopic dermatitis, contact dermatitis, and psoriasis (Grice, 1980; 
Pinnagoda et a/, 1989; Marks et al, 1990; Halkier-Sorensen and 
Thastrup-Pedersen, 1991) could be re lated to the abnormally high 
proteolytic activity observed in these disorders. Further, our studies 
indicate that serine protease inhibitors, particularly of the plasmin-
ogen/plasmin system, can have beneficial effects on barrier ho-
meostasis in both mice and humans after a variety of different 
insults . 
Previous studies have demonstrated that repeated insults by 
treatrnent with acetone or tape stripping produces epidermal hy-
perplasia (Denda et a/, 1996). Moreover, the magnitude of the 
epidermal hyperplasia was directly correlated with both the degree 
and the duration of barrier disruption (Denda et al, 1996). Occlu-
sion with a water-impermeable membrane, however, did not 
prevent the epidermal hyperplasia, indicating that barrier disruption 
was not the cause of these pathologic changes but, rather, was a 
marker for the degree of injury (Denda et a/, 1996) . In the current 
study, we demonstrate that t-AMCHA treatment decreases the 
epidermal hyperplasia that occurs after repeated injury to the 
stratum corneum. Furthermore, previous studies have demon-
strated that topical t-AMCHA reduces the hyperplastic dry scaly 
skin that is induced by SDS treatment (Kitamura el al, 1995). This 
indicates that t-AMCHA not only accelerates barrier repair but also 
provides other potential benefits after epidermal injuries. 
Normal epidermis contains many of the components of the 
plasminogen system (Kramer et al, 1995). Urokinase- type plasmin-
ogen activator (uPA) is the predominant plasminogen activator in 
normal epidermis, but in disease states such as psoriasis, the quantity 
of tissue-type plasminogen activator increases Oensen et a/, 1988; 
Spiers et a/, 1994) . Natural inhibitors of uPA and tissue-type 
plasminogen activator, PAI-l and PAI-2, are also made by kerati-
nocytes (Hashimoto el a/, 1989; Romer et a/, 1991). When the 
balance of activation versus inhibition results in the activation of 
plasminogen, this leads to the conversion of plasminogen to 
plasmin. Plasmin is a serine protease that can hydrolyze a wide 
variety of extracellular proteins, including other proteases leading 
to their activation (Vassalli et a/, 1991.). Thus, plasminogen activa-
tion leads to a cascade of proteolytic events that may effect a large 
number of extracellulm· proteins thereby altering cell function . 
The importance of the plasminogen plasmin cascade in epidermal 
biology and pathophysiology has been suggested by a large number 
of studies (Kramer et a/, 1995). After wounding the epidermis, there 
is an increase in uPA and its receptor on kerat:inocyte outgrowths, 
suggesting that the focal formation of plasmin and increased local 
extracellular proteolysis may be important in keratinocyte migra-
tion (Grondahi-Hansen et a/, 1988; Romer et a/, 1991, 1994) . 
Targeted disruption of the plasminogen gene results in impaired 
wow1d healing (Romer eta/, 1996). In several disease states, such as 
psoriasis and pemphigus, the expression of components of the 
plasminogen activation system are increased, suggesting that in-
creased plasmin activity may contribute to disease manifestations 
Oensen et al, 1988, 1990; Baird eta/, 1990; Spiers et al, 1994). 
Moreover, the administration of plasmin to skin organ cultures 
induces acantholysis and the ability of pemphigus IgG to induce 
acantholysis is blocked by PAl-2, an inhibitor of plasminogen 
activation (Hunziker and Vassalli, 1987; Spiers et al, 1994). Lastly, 
the overexpression ofhuman PAI-l in transgenic mice results in a 
greatly thickened stratum corneum, suggesting a role for plasmin in 
epidermal desquamation (Lyons-Giordano and Lazarus, 1995). 
Along similar lines in keratinocytes grown in the absence of thyroid 
hormone, plasminogen activator activity is decreased 70-80% and 
there is a decreased shedding of cornified cells, but conversely, the 
addition of retinoic acid increases both uP A and tissue~type plas-
minogen activator activity and decreases cell cohesion (Isseroff eta/, 
1989). T hus, there are many avenues by which the activation of the 
VOL. 109, NO. J ULY 1997 t-AMCHA ACCELERATES BARR.IER RECOVERY 89 
c TS 
TS-P 
Figure 6. Barrier disruption with tape stripping induces epidermal proteolytic activity. Human forearm skin was trc:~ted un til TEWL reached 10 
mg per cm2 per h. Proteolytic activ ity is barely detectable in the epidermis of untreated control skin (C). Two hours after tape stripping, the proteolytic 
activity increased in the epidermis (disappearance of light green color over epidermis) (TS). T his epidennal proteolytic activity was decreased in 
plasminogen-free substrate gel (TS-P) and was tota ll y inhibited by t-AMCHA (TS + TA) even in the presence of plasminogen. Scale bar, 100 p.m . 
plasminogen plasmin system cou ld potentially alter epidermal func-
tion. 
We have demonstrated in both mice and humans that the topical 
application of t-AMCHA, which inhibits plasminogen activation, 
accelerated barrier recovery after barrier disruption by acetone 
treatment, SDS treatment, or tape stripping. Moreover, the epider-
mal hyperplasia that is induced by repeated epidermal injuries by 
either acetone treatment or tape stripping is decreased by topical 
t-AMCHA treatment. These res ults suggest that manipulations that 
injure the stratum corneum activates the plasminogen/plasmin 
system. This increase in extracellular protease activity is detrimental 
to barrier repair and may induce pathologic changes in the skin . 
Thus, a new potential stra tegy from improving barri er repair and 
decreasing the pathology associated with cutaneous injury may be 
to inhibit the ac tivation of plasminogen or the activity of plasmin . 
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